Browse categories and answer follow-up questions to refine your symptom profile.
Approach to the Critical Patient
Immediate stabilization
Resuscitation priorities
Airway protection trigger
Ongoing massive hematemesis
GCS < 13
Shock triggers
SBP < 90 mmHg
MAP < 65 mmHg
Lactate rising
Large-bore access
2 peripheral IVs
Rapid infuser consideration
Hemorrhage control bundle
Mechanical compression for external bleeding
Tourniquet for uncontrolled extremity bleeding
Pelvic binder for suspected pelvic fracture
Massive transfusion activation triggers
Ongoing hemodynamic instability with suspected major bleed
Transfusion requirement escalating
Targets and monitoring
Physiologic targets
MAP ≥ 65 mmHg
Hemoglobin trend stabilization
Platelets ≥ 50 x 10^9/L for major bleeding
Platelets ≥ 100 x 10^9/L for intracranial bleeding or neurosurgery
Fibrinogen ≥ 1.5 g/L
Temperature ≥ 36 C
Ionized calcium within local reference range
Monitoring
Cardiac monitor
Rate and rhythm for shock physiology
Frequent vitals
Every 5-15 minutes during active resuscitation
Foley consideration
Urine output trend for shock
Arterial line trigger
Refractory shock
Vasoactive infusion
Anticoagulant identification and reversal triggers
Anticoagulant exposure classification
Vitamin K antagonist
Warfarin
Direct thrombin inhibitor
Dabigatran
Factor Xa inhibitor
Apixaban
Rivaroxaban
Edoxaban
Betrixaban
Heparins
Unfractionated heparin
Low molecular weight heparin
Indirect Xa inhibitor
Fondaparinux
Major bleeding definition
Hemodynamic compromise
Critical site bleeding
Intracranial
Intraspinal
Intraocular with vision threat
Pericardial
Airway
Retroperitoneal
Overt bleed with significant hemoglobin drop
Transfusion requirement
Reversal activation principles
Life-threatening bleeding
Immediate reversal pathway
Major bleeding
Reversal pathway plus source control
Non-major bleeding
Hold agent and supportive care pathway
Source control and consultation triggers
Source control pathways
GI bleeding
GI consult for endoscopy timing
Intracranial bleeding
Neurosurgery consult
Neurocritical care consult
Trauma
Trauma team activation
Pelvic or solid organ bleeding
Interventional radiology consult
Hematuria with clot retention
Urology consult
Postpartum or uterine bleeding
Obstetrics consult
Specialist triggers
Hematology consult
Unclear agent
Refractory coagulopathy
Suspected superwarfarin exposure
Poison center or toxicology consult
Unknown ingestion
Massive overdose
PITFALLS
Common errors
Reversal delay while awaiting definitive imaging in suspected intracranial bleed
Under-recognition of mixed antithrombotic therapy
Anticoagulant plus antiplatelet
Reliance on normal INR to exclude DOAC effect
Failure to correct hypothermia and hypocalcemia during massive transfusion
PEARLS
High-yield principles
Agent-specific reversal when available
PCC for warfarin-associated major bleeding preferred over plasma in many protocols
Dabigatran uniquely dialyzable compared with factor Xa inhibitors
Restart decision individualized after hemostasis and bleed site risk
History
Medication and exposure details
Anticoagulant timeline
Agent name and formulation
Indication
Atrial fibrillation
VTE treatment
Mechanical valve
Prophylaxis
Last dose time
Missed doses pattern
Recent dose changes
Adherence concerns
Concomitant medications
Antiplatelets
Aspirin
P2Y12 inhibitors
NSAIDs
SSRIs and SNRIs
Antibiotics interacting with warfarin
Amiodarone and other CYP interactions
Renal and hepatic function context
Chronic kidney disease history
Cirrhosis history
Recent dehydration or illness
Bleeding characterization
Bleeding pattern
Hematemesis
Melena
Hematochezia
Hematuria
Epistaxis
Gingival bleeding
Heavy menstrual bleeding
Bruising and hematomas
Severity markers
Syncope or presyncope
Dyspnea
Chest pain
New focal neurologic symptoms
Headache onset and progression
Trauma and procedures
Fall or head impact
Recent surgery
Recent dental procedure
Recent lumbar puncture or neuraxial anesthesia
Thrombotic risk context
High thrombosis-risk conditions
Mechanical heart valve
VTE within past 3 months
Severe thrombophilia history
Prior cardioembolic stroke
Baseline stroke or VTE risk tools availability
CHA2DS2-VASc documented score
Prior VTE provoked vs unprovoked
Bleeding risk contributors
Bleeding risk factors
Prior GI bleed
Prior intracranial bleed
Alcohol use disorder
Falls risk
Malignancy
Thrombocytopenia history
Physical Exam
Hemodynamics and perfusion
Perfusion assessment
Mental status
Capillary refill
Skin temperature and mottling
Volume status clues
Orthostatic changes when safe
Jugular venous distension absence or presence
Shock physiology clues
Tachycardia
Narrow pulse pressure
Cool extremities
Site-focused bleeding exam
External bleeding search
Scalp and face
Oral cavity
Skin hematomas
Abdominal and flank
Tenderness
Distension
Cullen sign
Grey Turner sign
Rectal exam when indicated
Melena
Hematochezia
Pelvic and vaginal bleeding when indicated
Active bleeding
Products of conception consideration in pregnancy
Neurologic
Intracranial bleeding screen
GCS
Pupillary size and reactivity
Focal deficits
Seizure activity
PITFALLS
Missed findings
Retroperitoneal bleed without overt external signs
Occult head injury in anticoagulated fall
Differential Diagnosis
Life-threatening etiologies
Major bleeding syndromes
Intracranial hemorrhage
ICD-10 I61.9
SNOMED intracerebral hemorrhage
Upper GI bleed
ICD-10 K92.2
Ruptured abdominal aortic aneurysm
ICD-10 I71.4
Retroperitoneal hemorrhage
ICD-10 R58
Hemopericardium with tamponade
Hemothorax
Coagulopathy contributors and mimics
Non-anticoagulant coagulopathy
Liver failure coagulopathy
DIC
Uremic platelet dysfunction
Acquired hemophilia
Anticoagulant complications
Warfarin-associated bleeding
ICD-10 D68.32
DOAC-associated bleeding
Heparin-associated bleeding
Non-bleeding anemia causes
Hemolysis
Bone marrow suppression
Laboratory Tests
Core labs
Initial panel
Complete blood count for bleeding concern
Hemoglobin trend
Platelet count
Electrolytes and renal function
Creatinine in umol/L
Liver panel for synthetic function context
Coagulation screen
INR
aPTT
Type and screen
Crossmatch trigger for major bleed
Fibrinogen
Low value trigger for cryoprecipitate
VBG or ABG when shock suspected
pH
PaCO2 in mmHg
PaO2 in mmHg
Lactate in mmol/L
Anticoagulant-specific testing
Warfarin effect
INR correlation with intensity
Bleeding can occur at any INR
Unfractionated heparin effect
aPTT interpretation context
Anti-Xa heparin assay when available
LMWH effect
Anti-Xa LMWH assay when available
Dabigatran effect
Thrombin time sensitivity
Dilute thrombin time when available
Ecarin clotting time when available
Factor Xa inhibitor effect
Anti-Xa calibrated assay when available
INR unreliability for drug effect
Transfusion and resuscitation labs
Ongoing major hemorrhage monitoring
Hemoglobin recheck frequency
Every 2-4 hours during active bleeding
INR and aPTT reassessment after reversal
Fibrinogen reassessment after replacement
Ionized calcium monitoring during massive transfusion
PITFALLS
Test limitations
Normal INR does not exclude apixaban or rivaroxaban effect
aPTT can be normal with clinically relevant DOAC levels
Diagnostic Tests
Scoring Systems
Risk and severity tools
Major bleeding classification frameworks
Critical site bleeding as automatic major bleed
Hemodynamic compromise as major bleed
GI bleeding risk tools
Glasgow-Blatchford score for upper GI bleed triage
Higher score association with need for intervention
Intracerebral hemorrhage severity
ICH Score for mortality risk discussion
Not a sole determinant of goals-of-care decisions
MRI
MRI indications
Spinal epidural hematoma concern
Back pain
Weakness
Bowel or bladder dysfunction
Subacute intracranial bleed evaluation when CT equivocal
MRI constraints
Hemodynamic instability as contraindication
MRI safety screening requirements
CT
CT head
Any head trauma on anticoagulant
Low threshold imaging
New neurologic deficit
Severe headache
CT angiography
Suspected active arterial bleeding site localization
GI bleed with hemodynamic instability when endoscopy delayed
CT abdomen and pelvis
Suspected retroperitoneal bleed
Flank pain with falling hemoglobin
Ultrasound (or US)
POCUS in shock
Cardiac views for pericardial effusion
IVC assessment as adjunct
FAST or eFAST
Trauma evaluation for free fluid
Hemothorax evaluation
Procedural guidance
Vascular access assistance in shock
Endoscopy and angiography
Endoscopy considerations
Upper GI bleed timing coordination with GI
Airway protection planning for massive hematemesis
Interventional radiology
Embolization candidacy for ongoing arterial bleed
Disposition
Level of care
ICU indications
Hemodynamic instability
Ongoing transfusion requirement
Intracranial hemorrhage
Need for urgent anticoagulant reversal agent infusion or complex monitoring
Step-down or ward considerations
Hemostasis achieved
Stable hemoglobin trend
No critical site bleed
Discharge considerations
Minor bleeding resolved
Reliable follow-up within 24-72 hours
Clear anticoagulant interruption plan
Transfer and specialty destination
Transfer triggers
Neurosurgical capability requirement
Interventional radiology requirement not available
Endoscopy capability requirement not available
Anticoagulant restart planning
Restart decision framework
Critical organ bleed
Delayed restart typical
Source not secured
Delayed restart typical
High thrombotic risk
Earlier restart consideration after hemostasis
Low thrombotic risk
Discontinuation consideration
Treatment
General measures
Immediate actions
Hold anticoagulant
Document last dose time estimate
Local hemostatic measures
Direct pressure
Topical hemostatic agents when appropriate
RBC transfusion strategy
Symptomatic anemia
Ongoing hemorrhagic shock
Platelet transfusion strategy
Platelets < 50 x 10^9/L with major bleeding
Platelets < 100 x 10^9/L with intracranial bleeding
Fibrinogen replacement
Cryoprecipitate for fibrinogen < 1.5 g/L in major bleed
Tranexamic acid
1 g IV over 10 minutes for life-threatening bleeding
1 g IV over 8 hours continuation in selected protocols
Calcium replacement during massive transfusion
Ionized calcium guided dosing
Vitamin K antagonist reversal (warfarin)
Warfarin reversal pathway
Four-factor PCC plus vitamin K for major bleeding
PCC dosing per INR and weight
INR 2-4
25 IU/kg
INR 4-6
35 IU/kg
INR > 6
50 IU/kg
Maximum dose per local protocol
Vitamin K 10 mg IV for life-threatening bleeding
Infusion over 20-60 minutes to reduce reaction risk
Repeat INR reassessment
30-60 minutes after PCC
Additional PCC consideration for persistent elevation with ongoing bleeding
Plasma use considerations
PCC unavailable
Volume overload risk acknowledgment
Evidence and guideline alignment
Rapid reversal with PCC favored over plasma in many guidelines for warfarin-associated intracranial hemorrhage (Class I recommendation in ICH-focused guidance)
Direct thrombin inhibitor reversal (dabigatran)
Dabigatran pathway
Idarucizumab
5 g IV total
2.5 g IV x 2 doses
Back-to-back administration acceptable
Rebound anticoagulant effect risk
Consider repeat labs and clinical reassessment
Activated charcoal
Recent ingestion window
Within 2 hours typical consideration
Airway protected requirement if altered mental status
Hemodialysis
Life-threatening bleeding with renal failure or massive exposure
Significant dabigatran removal compared with factor Xa inhibitors
Evidence and guideline alignment
Specific antidote use supported in intracranial hemorrhage guidance (Class I recommendation in ICH-focused guidance)
Factor Xa inhibitor reversal (apixaban, rivaroxaban, edoxaban, betrixaban)
Factor Xa inhibitor pathway
Andexanet alfa when available and appropriate
Dosing per agent and last dose timing per institutional protocol
Thrombotic risk counseling and monitoring
Four-factor PCC alternative
50 IU/kg commonly used in many institutional pathways
Maximum dose per local protocol
Activated charcoal
Recent ingestion window
Within 2 hours typical consideration
Airway protected requirement if altered mental status
Evidence and guideline alignment
Andexanet alfa supported for factor Xa inhibitor reversal in ICH-focused guidance (Class IIa in many summaries)
PCC used when andexanet unavailable or unsuitable in many pathways
Unfractionated heparin reversal
UFH pathway
Protamine
1 mg per 100 units heparin given in previous 2-3 hours
Maximum 50 mg per dose in many protocols
Slow IV administration to reduce hypotension risk
Monitoring
aPTT or anti-Xa reassessment after protamine
Evidence alignment
Protamine use suggested for life-threatening bleeding in heparin therapy guidance
Low molecular weight heparin reversal (enoxaparin and similar)
LMWH pathway
Protamine partial reversal
Within 8 hours of LMWH dose
1 mg protamine per 1 mg enoxaparin equivalent
8-12 hours after dose
0.5 mg protamine per 1 mg enoxaparin equivalent
Second dose consideration
0.5 mg protamine per 1 mg enoxaparin equivalent if ongoing bleeding
Anti-Xa monitoring limitations
Clinical hemostasis as primary endpoint
Fondaparinux-associated bleeding
Fondaparinux pathway
No specific antidote widely available
PCC consideration in life-threatening bleeding per institutional protocol
Supportive care emphasis
Source control priority
Adjuncts and special therapies
Desmopressin consideration
Suspected uremic platelet dysfunction
Antiplatelet co-exposure with critical bleeding site
Antifibrinolytic coordination
Trauma protocols alignment when trauma suspected
Thrombosis mitigation after reversal
Mechanical VTE prophylaxis when safe
Restart anticoagulant planning after hemostasis
Evidence framework summary
Guideline concepts
ACC consensus pathway focus
Bleeding severity stratification
Temporary interruption
Reversal for life-threatening bleeding
Restart assessment after control
Special Populations
Pregnancy
Pregnancy considerations
Physiologic hypercoagulability context
High thrombosis risk if anticoagulant withheld
Preferred anticoagulants in pregnancy context
LMWH common outpatient agent
Reversal and consultation
Obstetrics involvement for uterine or postpartum bleeding
Neuraxial anesthesia timing awareness
Imaging selection
CT when life-threatening hemorrhage suspected
MRI for spinal epidural hematoma concern when stable
Geriatric
Older adult considerations
Falls and head trauma threshold
Low threshold CT head
Renal clearance changes
DOAC accumulation risk
Polypharmacy interactions
Warfarin interaction risk
Transfusion tolerance considerations
Heart failure risk with plasma
Pediatrics
Pediatric considerations
Weight-based dosing requirement
PCC and protamine dosing verification
Anticoagulant exposure context
Congenital heart disease
ECMO or ventricular assist device
Specialty consultation
Pediatric hematology involvement early
Antidote availability
Institution-specific pediatric stocking policies
Background
Epidemiology
Frequency and context
Anticoagulant use prevalence rising with atrial fibrillation and VTE indications
Major bleeding risk varies by agent and patient comorbidity
Intracranial hemorrhage as high-mortality anticoagulant complication
Pathophysiology
Mechanisms
Warfarin effect
Reduced vitamin K dependent clotting factors
Dabigatran effect
Direct thrombin inhibition
Factor Xa inhibitor effect
Inhibition of factor Xa in coagulation cascade
Heparin effect
Antithrombin-mediated inhibition of thrombin and factor Xa
Hemorrhage physiology
Coagulopathy plus local vascular injury as common pathway
Shock triad
Hypothermia
Acidosis
Coagulopathy
Therapeutic Considerations
Reversal strategy principles
Agent-specific antidote preference when available
PCC rapid factor replacement for warfarin-associated major bleeding
Vitamin K for sustained warfarin reversal
Dialysis utility mainly for dabigatran
Risk tradeoffs
Thrombotic event risk after reversal agents
Restart timing individualized by bleed site and indication
Evidence framing
Intracranial hemorrhage guidance emphasizes rapid reversal to limit hematoma expansion
ACC pathway emphasizes severity-based reversal and structured restart assessment
Patient Discharge Instructions
copy discharge instructions
Discharge guidance
Anticoagulant plan
Hold or restart date and time written clearly
Do not double-dose if a dose was missed unless instructed
Medication safety
Avoid NSAIDs unless clinician-approved
Avoid new over-the-counter supplements without checking interactions
Alcohol moderation
Follow-up
Primary care or anticoagulation clinic within 24-72 hours
INR recheck timing if on warfarin
Renal function recheck timing if on DOAC and recent illness
Return to ED immediately for
Any head injury or fall
Severe headache
New weakness, numbness, speech change, confusion
Fainting or near-fainting
Vomiting blood
Black or bloody stool
Blood in urine with clots
Heavy vaginal bleeding
Shortness of breath or chest pain
Bleeding prevention
Soft toothbrush and gentle flossing
Electric razor
Avoid high-risk contact activities until cleared
References
Clinical guidelines and consensus
Guideline sources
AHA/ASA guideline for spontaneous intracerebral hemorrhage
Warfarin-associated ICH rapid reversal recommendations
Dabigatran reversal with idarucizumab recommendations
Factor Xa inhibitor reversal with andexanet alfa considerations
ACC expert consensus decision pathway for bleeding on oral anticoagulants
Bleeding severity stratification
Reversal agent decision support
Restart anticoagulation considerations
Neurocritical Care Society and Society of Critical Care Medicine guideline for antithrombotic reversal in intracranial hemorrhage
PCC preference over plasma for VKA-associated ICH in many recommendations
American Society of Hematology guidelines on anticoagulation therapy
Protamine suggestions for life-threatening bleeding on UFH or LMWH
Evidence-based reviews and tools
Supporting evidence categories
Comparative studies of PCC versus plasma for rapid INR correction
Antidote trials and post-marketing safety for idarucizumab and andexanet alfa
SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.